TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6104840

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31984668

Group type: EXPERIMENTAL
Intervention: Weight Loss + Maintenance arm (16 + 12 sessions)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Weight Loss Only arm (16 sessions)
Number of subjects: 440
Study: 29444721

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT-G) delivered by lay community health workers (LCHWs), 12 sessions
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Children of caregivers who received IPT-G
Number of subjects: 142

Group type: COMPARATOR
Intervention: Caregivers receiving treatment as usual (TAU)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Caregivers receiving IPT-G
Number of subjects: 142
Study: 27217448

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study: 25648055

Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training (N = 37)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Aerobic training (N = 36)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Social group (N = 36)
Number of subjects: 109
Study: 23823344

Group type: EXPERIMENTAL
Intervention: 0.3% chlorine dioxide (ClO2) mouthrinse
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate (CHX)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.05% CPC
Number of subjects: 11
Study: 22043076

Group type: EXPERIMENTAL
Intervention: Pour-on ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injectable ivermectin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 0
Study: 18504096

Group type: EXPERIMENTAL
Intervention: African American patients (AA)
Number of subjects: 898

Group type: COMPARATOR
Intervention: European American patients (EA)
Number of subjects: 898
Study: 16573786

Group type: EXPERIMENTAL
Intervention: Presence of portal hypertensive gastropathy (PHG)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Mucosal mosaic pattern
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Red marks
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Gastric antral vascular ectasia (GAVE) features
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Independent correlates of PHG
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Independent correlates of GAVE
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Association between PHG and esophageal varices
Number of subjects: 1016
Study: 12759758

Group type: EXPERIMENTAL
Intervention: Repetitive incremental lifting and lowering (RILL) at 10 lifts/min to voluntary fatigue
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Repetitive incremental lifting and lowering (RILL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory, hemodynamic and body composition variables
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Inclusion of left side OXY/BV responses
Number of subjects: 32
Study: 10947577

Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for a one month reduction in waiting time for cataract surgery.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lost consumer surplus due to cataract surgery queue.
Number of subjects: 0
Study: 8853469

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (EPI)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 2054270

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa combination (Sinemet Plus)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6357631

Group type: EXPERIMENTAL
Intervention: 0.1mg Sulprostone gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5mg PGE2 gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.05mg Sulprostone gel
Number of subjects: 30
Study: 31770060

Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide, and dexamethasone (VRD) followed by autologous transplantation and two consolidation courses with VRD
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Maintenance (lenalidomide and ixazomib)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Undetectable MRD
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Revised International Staging System III status and positive MRD
Number of subjects: 458
Study: 30411328

Group type: EXPERIMENTAL
Intervention: Mammography screening participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participation in mammography screening
Number of subjects: 0
Study: 30316999

Group type: EXPERIMENTAL
Intervention: iCanCope program (pain self-management skills training including personalized CBT-based coping skills such as deep breathing, relaxation, and cognitive skills)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attention control group (self-guided website with education about SCD)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: iCanCope program
Number of subjects: 160
Study: 27894295

Group type: EXPERIMENTAL
Intervention: WebCONSORT
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control
Number of subjects: 324
Study: 24571619

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration using the Eliminate aspiration catheter (Terumo Medical Supply, Japan)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional primary percutaneous coronary intervention (PCI)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional primary PCI
Number of subjects: 128
Study: 22512481

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (fluorouracil 500 mg/m²/day during fractions 1 to 5 and 16 to 20 of radiotherapy, mitomycin C 12 mg/m² on day 1)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 360
Study: 20079760

Group type: EXPERIMENTAL
Intervention: Intervention (n=54): Supporters received monthly contacts from a counselor about providing effective support.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (n=28): Supporters were not contacted.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intervention (n=54) at end of pregnancy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intervention (n=54) at 3 months postpartum
Number of subjects: 82
Study: 18164334

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 29
Study: 16149980

Group type: EXPERIMENTAL
Intervention: Music intervention group (n=60)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo group (n=60)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (n=60)
Number of subjects: 180
Study: 13130460

Group type: EXPERIMENTAL
Intervention: RAPIT program (2-year intensive exercise program)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 309
Study: 10382786

Group type: EXPERIMENTAL
Intervention: IL-1ra at a dose of 1 mg/kg/h (n = 20)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: IL-1ra at a dose of 2 mg/kg/h (n = 22)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 71
Study: 8808137

Group type: EXPERIMENTAL
Intervention: IV nicotine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IV saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard 1-mg cigarette
Number of subjects: 6
Study: 1418276

Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms.kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glycopyrrolate (5 micrograms.kg‐1)
Number of subjects: 100
Study: 6326178

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 30148994

Group type: EXPERIMENTAL
Intervention: Double-guidewire technique (DGWT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wire-guided cannulation over a pancreatic stent (WGC-PS)
Number of subjects: 100
Study: 29385990

Group type: EXPERIMENTAL
Intervention: Urox® (Crataeva nurvala stem bark, Equisetum arvense stem, Lindera aggregata root)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 27426680

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach for vaginal cuff closure
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vaginal route for vaginal cuff closure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach and Vaginal route
Number of subjects: 70
Study: 25137036

Group type: EXPERIMENTAL
Intervention: trans-resveratrol (500 mg) three times per day for 90 days
Number of subjects: 24
Study: 22704095

Group type: EXPERIMENTAL
Intervention: Ureteral advancement during laparoscopic extravesical ureteral reimplantation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-advancement during laparoscopic extravesical ureteral reimplantation
Number of subjects: 30
Study: 20979893

Group type: EXPERIMENTAL
Intervention: Quadrant posterior minimally invasive surgery system (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Traditional open surgery (n = 31)
Number of subjects: 61
Study: 18570574

Group type: EXPERIMENTAL
Intervention: ciprofloxacin-metronidazole
Number of subjects: 244

Group type: COMPARATOR
Intervention: piperacillin-tazobactam
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: appendicitis patients
Number of subjects: 244

Group type: COMPARATOR
Intervention: other infections
Number of subjects: 244
Study: 15850121

Group type: COMPARATOR
Intervention: Pen tablet system for evaluation of hand motion control function; subjects instructed to tap 50 times with each hand.
Number of subjects: 13
Study: 12418296

Group type: EXPERIMENTAL
Intervention: Enoxaparin 0.8 mg/kg, subcutaneous every 12 hours during 5 days
Number of subjects: 203

Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin during 5 days, by infusion
Number of subjects: 203
Study: 10321676

Group type: EXPERIMENTAL
Intervention: ACLS simulation program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Textbook review
Number of subjects: 45
Study: 8166101

Group type: EXPERIMENTAL
Intervention: Fuji II LC light-activated glass polyalkenoate cement (GC Industrial Co., Tokyo, Japan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: System I+ composite bonding resin (Ormco Corp., Glendora, Calif.)
Number of subjects: 0
Study: 3254762

Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Glycyl-L-tyrosine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine and Glycyl-L-tyrosine
Number of subjects: 21
Study: 29576126

Group type: EXPERIMENTAL
Intervention: Fused B-mode and elastography videos with 0.25 ml volumes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fused B-mode and elastography videos
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fused elastography
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.25 ml volumes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1 ml volumes
Number of subjects: 22
Study: 23848989

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW/QW)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW/QW)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Etanercept (both dosing regimens)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 270
Study: 22921386

Group type: EXPERIMENTAL
Intervention: Mobile phone SMS intervention
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard follow‐up appointments (Control)
Number of subjects: 258
Study: 20557313

Group type: EXPERIMENTAL
Intervention: 80 mg aspirin per day for 6 months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin per day for 6 months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Both doses of aspirin
Number of subjects: 106
Study: 18596733

Group type: EXPERIMENTAL
Intervention: High-dose epoetin-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose epoetin-alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High hemoglobin arm
Number of subjects: 0
Study: 16059627

Group type: EXPERIMENTAL
Intervention: Nasal spray salmon calcitonin (CT‐NS)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 12870055

Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10235588

Group type: EXPERIMENTAL
Intervention: Bismuth plus metronidazole and amoxicillin (group A)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxicillin (group B)
Number of subjects: 126

Group type: COMPARATOR
Intervention: H. pylori-positive patients post-treatment
Number of subjects: 126
Study: 8638836

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 10
Study: 1472937

Group type: EXPERIMENTAL
Intervention: Low dose alpha 2B interferon (9 mU/week) in combination with oral chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral chemotherapy only (control group)
Number of subjects: 0
Study: 6329567

Group type: EXPERIMENTAL
Intervention: Interferon alpha
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisone and azathioprine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisone, azathioprine, and OKT3 antibody
Number of subjects: 32
Study: 31048448

Group type: EXPERIMENTAL
Intervention: Enhanced stroke self-management programme (COMBO-KEY) plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 0
Study: 29288764

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib (150 mg once daily and 360 mg twice daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Erlotinib plus placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Erlotinib plus tivantinib
Number of subjects: 109
Study: 27567363

Group type: EXPERIMENTAL
Intervention: Nifedipine (80mg daily until labor, max 18 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50
Study: 25381774

Group type: EXPERIMENTAL
Intervention: Telemedicine for paediatric retrieval consultations
Number of subjects: 160

Group type: COMPARATOR
Intervention: Telephone for paediatric retrieval consultations
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 160
Study: 23111148

Group type: EXPERIMENTAL
Intervention: Medical-grade honey applied in addition to standard CVC-site dressing and disinfection with 0.5% chlorhexidine in 70% alcohol.
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard care (CVC-site dressing and disinfection with 0.5% chlorhexidine in 70% alcohol).
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Medical-grade honey
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 235
Study: 19937752

Group type: EXPERIMENTAL
Intervention: Dyspnea-related anxiety and distress rated on the Modified Borg Scale after a 6-minute walk and an incremental treadmill test
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dyspnea-related anxiety and distress
Number of subjects: 103
Study: 17927634

Group type: EXPERIMENTAL
Intervention: Dentifrice containing salivary substitutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 20
Study: 15843333

Group type: EXPERIMENTAL
Intervention: School-wide curriculum-based programs presented to students
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: In-service presentations to school staff
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Self-report screening programs for students
Number of subjects: 210
Study: 11994701

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zafirlukast (80 mg twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of loratadine and zafirlukast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of zafirlukast and loratadine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Loratadine alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zafirlukast alone vs combination with loratadine
Number of subjects: 16
Study: 9708136

Group type: EXPERIMENTAL
Intervention: Educational and behavioral intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 108
Study: 7843449

Group type: EXPERIMENTAL
Intervention: Alpha-blocker (bunazosin) 2 mg/d for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (two tablets per day for 6 months)
Number of subjects: 34
Study: 1903599

Group type: EXPERIMENTAL
Intervention: Enteral glutamine infusion at graded rates (0 to 126 mmol/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enteral glutamine infusion at 46.8 mmol/h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enteral glutamine infusion
Number of subjects: 10
Study: 7327784

Group type: EXPERIMENTAL
Intervention: Pomerleau and Pomerleau's 1977 manual
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Danaher and Lichtenstein's 1978 manual
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40
Study: 30597688

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 0.1, 0.2, 0.5, 1.0 mg/kg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Midazolam 0.045 mg/kg (active placebo)
Number of subjects: 99
Study: 28768921

Group type: EXPERIMENTAL
Intervention: Evacetrapib 130 mg daily for 12 weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo/atorvastatin
Number of subjects: 149
Study: 26105582

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day) for 8 weeks in obese patients without T2DM
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day) for 8 weeks in obese patients with T2DM
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day) and pioglitazone (15 mg/day) combination for 8 weeks in obese patients with T2DM
Number of subjects: 44
Study: 24389932

Group type: EXPERIMENTAL
Intervention: Mild hyperthermia therapy (body core temperature 38.6 °C) combined with multimodal inpatient rehabilitation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Multimodal inpatient rehabilitation alone (control group)
Number of subjects: 88
Study: 22464343

Group type: EXPERIMENTAL
Intervention: Rapid genotyping group (CYP2C19*2 carriers treated with 10 mg prasugrel daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment group (CYP2C19*2 carriers treated with 75 mg clopidogrel daily)
Number of subjects: 200
Study: 20703198

Group type: EXPERIMENTAL
Intervention: Fluoxetine 10-60 mg/day for 12 weeks
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Fluoxetine continuation
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 17546266

Group type: EXPERIMENTAL
Intervention: DLC coated stent (Phytis)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Uncoated stent (Penta)
Number of subjects: 180
Study: 15777603

Group type: EXPERIMENTAL
Intervention: Salmeterol HFA MDI 50 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol CFC MDI 50 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol HFA MDI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol CFC MDI
Number of subjects: 0
Study: 12482334

Group type: EXPERIMENTAL
Intervention: Embolization therapy with polyvinyl alcohol foam (Ivalon) as a single agent
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chemoembolization using polyvinyl alcohol foam mixed with 750 mg/m2 of 5‐fluorouracil and 9 million units of interferon
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with extrahepatic disease
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with liver-only metastases
Number of subjects: 50
Study: 9588435

Group type: EXPERIMENTAL
Intervention: Sumatriptan injection (6 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 8575241

Group type: EXPERIMENTAL
Intervention: Indapamide treatment (2.5 mg)
Number of subjects: 5665

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 5665
Study: 2243350

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 6 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 12 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 24 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 36 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 48 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 60 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.) at 72 hr post-morphine (18 mg/70 kg or 30 mg/70 kg)
Number of subjects: 6
Study: 333556

Group type: EXPERIMENTAL
Intervention: sulphasomidine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: sulphalene
Number of subjects: 28